19 completed. 19 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 19 |
| Phase 2 | 4 | Completed 4 |
Follow Hypergammaglobulinemia: new trials by email Literature Review of Hypergammaglobulinemia trials Research Report on Hypergammaglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Best Practice, Ibrutinib - Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | Jennifer Woyach | 10 | 2020-10-23 | 2023-12-26 |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma Anakinra, Dexamethasone, Laboratory Biomarker Analysis - Indolent Plasma Cell Myeloma, Plasma Cell Myeloma | Phase 1 | Completed | Mayo Clinic | 14 | 2016-04-01 | 2020-03-25 |
| Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma PVX-410 - Smoldering Multiple Myeloma | Phase 1 | Completed | OncoPep, Inc. | 22 | 2012-11-01 | 2016-09-28 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Siltuximab - Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma | Phase 1 | Completed | Janssen Research & Development, LLC | 30 | 2010-10-01 | 2015-01-19 |
| A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma KW-2478, Bortezomib - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 95 | 2010-03-01 | 2024-04-25 |
| Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer therapeutic allogeneic lymphocytes, busulfan, cyclosporine - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 / Phase 2 | Completed | OHSU Knight Cancer Institute | 147 | 2005-06-01 | 2017-09-27 |
| Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma total marrow irradiation, melphalan, peripheral blood stem cell transplantation - Refractory Multiple Myeloma, Smoldering Multiple Myeloma | Phase 1 / Phase 2 | Completed | City of Hope Medical Center | 54 | 2004-11-01 | 2025-06-06 |
| Pyroxamide in Treating Patients With Advanced Cancer pyroxamide - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 2002-04-01 | 2013-06-05 | |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction imatinib mesylate, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 2001-08-01 | 2013-02-07 |
| EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer cilengitide - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Completed | Indiana University | 40 | 1999-12-01 | 2014-09-17 |
| PS-341 in Treating Patients With Advanced Cancer bortezomib - Leukemia, Lymphoma | Phase 1 | Completed | Mayo Clinic | 1999-11-01 | 2011-08-03 | |
| Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer filgrastim, cyclosporine, methylprednisolone - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 1 | Completed | Northwestern University | 1999-10-01 | 2012-06-01 | |
| Stem Cell Transplantation in Treating Patients With Hematologic Cancer anti-thymocyte globulin, filgrastim, cladribine - Chronic Myeloproliferative Disorders, Graft Versus Host Disease | Phase 1 | Completed | Northwestern University | 1999-10-01 | 2012-06-04 | |
| Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer recombinant interferon alfa, recombinant interleukin-12 - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 1998-08-01 | 2013-02-01 |
| Combination Chemotherapy in Treating Patients With Advanced Cancer fluorouracil, leucovorin calcium, topotecan hydrochloride - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Completed | NYU Langone Health | 30 | 1998-01-01 | 2011-03-28 |
| Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer monoclonal antibody A27.15, monoclonal antibody E2.3 - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Completed | University of Arizona | 27 | 1997-12-01 | 2010-03-16 |
| Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer carboplatin, docetaxel, ifosfamide - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 / Phase 2 | Completed | Cancer Treatment Centers of America | 30 | 1997-10-01 | 2013-03-26 |
| Decitabine in Treating Patients With Melanoma or Other Advanced Cancer decitabine - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Completed | California Cancer Consortium | 1997-05-01 | 2013-02-15 |
Multiple Myeloma (17) · Monoclonal Gammopathy of Undetermined Significance (16) · Burkitt Lymphoma (13) · Leukemia, Lymphocytic, Chronic, B-Cell (13) · Lymphoma, B-Cell, Marginal Zone (13) · Lymphoma, Follicular (13) · Lymphoma, Large B-Cell, Diffuse (13) · Lymphoma, Mantle-Cell (13) · Neoplasms, Plasma Cell (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Immunoglobulin Light-chain Amyloidosis (12) · Leukemia (12) · Leukemia, Hairy Cell (12) · Leukemia, Myeloid, Acute (12) · Leukemia, Myeloid, Chronic-Phase (12)
Hemic and Lymphatic Diseases (19) · Neoplasms (19) · Blood Protein Disorders (18) · Hematologic Diseases (18) · Immune System Diseases (18) · Immunoproliferative Disorders (18) · Paraproteinemias (18) · Cardiovascular Diseases (17) · Hemorrhagic Disorders (17) · Hemostatic Disorders (17) · Lymphoproliferative Disorders (17) · Neoplasms by Histologic Type (17) · Vascular Diseases (17) · Leukemia, Lymphoid (14)
Peripheral Blood Stem Cell Transplantation (4) · Filgrastim (3) · Lenalidomide (3) · Bortezomib (2) · Cyclophosphamide (2) · Cyclosporine (2) · Granulocyte Colony-Stimulating Factor (2) · Methylprednisolone (2) · Antilymphocyte Serum (1) · Busulfan (1) · Calcium Dobesilate (1) · Carboplatin (1) · Cilengitide (1) · Cladribine (1) · Cytogenetic Analysis (1)
City of Hope Medical Center (2) · Mayo Clinic (2) · National Cancer Institute (NCI) (2) · Northwestern University (2) · California Cancer Consortium (1) · Cancer Treatment Centers of America (1) · Indiana University (1) · Janssen Research & Development, LLC (1) · Jennifer Woyach (1) · Kyowa Kirin Co., Ltd. (1) · Memorial Sloan Kettering Cancer Center (1) · NYU Langone Health (1) · OHSU Knight Cancer Institute (1) · OncoPep, Inc. (1) · University of Arizona (1)
United States (19) · Belgium (1) · Philippines (1) · Russia (1) · United Kingdom (1)
Richard K. Burt, MD (2) · Ajay Nooka, MD (1) · Alex A. Adjei, MD, PhD (1) · George Somlo (1) · Howard S. Hochster, MD (1) · Jeffrey S. Weber, MD, PhD (1) · Jennifer A Woyach, MD (1) · John Lust (1) · Leonard B. Saltz, MD (1) · Loan Hoang-Sayag, MD (1) · Michael Kurman, MD (1) · Michael Lobell, MD (1) · Michael S. Gordon, MD (1) · Michael Wang, MD (1)
PMID 26853648, PMID 30128502, PMID 30562587
P30CA015083 (2), 2009 (1), P30CA016058 (1), P30CA016087 (1), P30CA023074 (1), U01CA062487 (1), U01CA062491 (1), U01CA062502 (1), U01CA062505 (1), U01CA069912 (1), U01CA099168 (1)